ERBB2 and non-small cell lung carcinoma: A phase II study of 26 patients with HER2-positive, advanced NSCLC, dacomitinib led to PR in 3 of 26 (11.5%) patients with HER2 mutations (25 insertion and 1 missense mutation) compared to no PR observed in 4 patients with HER2 amplification.